Wealthfront Advisers LLC bought a new stake in Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 106,055 shares of the medical instruments supplier's stock, valued at approximately $7,849,000. Wealthfront Advisers LLC owned 0.21% of Haemonetics at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares during the period. AlphaQuest LLC lifted its position in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares in the last quarter. KBC Group NV lifted its position in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after buying an additional 712 shares in the last quarter. iSAM Funds UK Ltd purchased a new stake in Haemonetics during the third quarter valued at approximately $204,000. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in Haemonetics during the fourth quarter valued at approximately $284,000. 99.67% of the stock is currently owned by institutional investors.
Shares of HAE traded up $0.17 during midday trading on Thursday, hitting $65.85. The company had a trading volume of 643,246 shares, compared to its average volume of 1,006,030. The company's 50 day moving average price is $68.90 and its 200 day moving average price is $75.49. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of 25.92, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.
Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.
A number of equities research analysts have recently commented on the company. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price target for the company. Raymond James reissued a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, Needham & Company LLC lowered their target price on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of "Moderate Buy" and a consensus price target of $101.67.
View Our Latest Research Report on HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.